What Is Acute Promyelocytic Leukemia?

Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia driven by a specific chromosomal rearrangement that causes immature white blood cells to pile up in the bone marrow, triggering a dangerous bleeding disorder that can kill within days. It is also, paradoxically, the most curable form of acute leukemia in adults. That transformation from one of the deadliest cancers to one with cure rates above 90 percent is one of the more remarkable stories in modern oncology, and it hinges on two drugs that work by destroying the very protein the disease creates.

What Happens Inside the Cells

APL begins with a genetic accident: a swap of material between chromosomes 15 and 17 creates a fusion gene called PML-RARα. The resulting protein does two things that together lock white blood cells in an immature state. First, it silences genes that would normally tell the cell to mature. Second, it disrupts PML, a protein that ordinarily acts as a tumor suppressor. The net effect is a growing mass of abnormal promyelocytes, cells stuck partway through development, crowding out normal blood production.¹

This fusion gene is not just a diagnostic marker. It is the disease. Almost everything that makes APL distinctive, from its bleeding tendency to its extraordinary drug sensitivity, traces back to PML-RARα. And because the disease depends so completely on a single molecular driver, eliminating that protein effectively eliminates the leukemia.

The Bleeding Emergency

APL’s most immediate danger is not the leukemia cells themselves but the severe clotting disorder they provoke. Patients often show up in the emergency room with uncontrolled bleeding, bruising, or sometimes life-threatening hemorrhage in the brain or lungs, even before anyone suspects leukemia. The coagulopathy is more complex than a simple clotting-factor shortage. APL cells trigger widespread activation of the clotting system while simultaneously ramping up fibrinolysis, the process that dissolves clots. The combination means the body is both using up its clotting factors and destroying whatever clots do form.²

Elevated D-dimer levels, a marker of clot breakdown, are a hallmark of this process and provide strong evidence that hyperfibrinolysis is a central driver of the bleeding.³ This is why the single most important step in managing APL is speed. Treatment with all-trans retinoic acid (ATRA) should begin the moment APL is clinically suspected, even before genetic confirmation arrives, because ATRA starts to reverse the coagulopathy quickly. Alongside drug therapy, aggressive transfusion support with platelets, fresh frozen plasma, and fibrinogen replacement is essential to keep the patient alive through the first critical hours and days.⁴

Early death, meaning death before or during the first weeks of treatment, remains the main reason patients with APL do not survive. In clinical trials the mortality numbers look excellent, but real-world data consistently show that a meaningful fraction of patients die from hemorrhage before they can fully benefit from therapy. Reducing early death is less about inventing new drugs and more about faster recognition, immediate ATRA, and intensive blood-product support.

How the Drugs Work

The two pillars of APL therapy are ATRA and arsenic trioxide (ATO). Both are “targeted” in the most literal sense: they physically attach to and destroy the PML-RARα fusion protein, though they attack different parts of it. ATRA binds the RARα portion, triggering the stuck promyelocytes to resume maturing into functional white blood cells. ATO binds directly to cysteine residues within the PML portion, causing the protein to clump together (oligomerize), become chemically tagged for disposal, and get degraded by the cell’s own recycling machinery.⁵

ATO also increases reactive oxygen species inside the cell, and this oxidative stress turns out to be part of the therapeutic mechanism. The oxidation forces PML-RARα molecules to form disulfide-linked multimers, which cluster into nuclear bodies, become tagged with a small protein called SUMO, and are then destroyed. Experiments with mutant versions of PML-RARα that cannot bind arsenic show a crippled drug response, confirming that direct arsenic binding is essential, not incidental, to the cure.⁶

When ATRA and ATO are combined, they clear PML-RARα transcripts faster and more completely than either drug alone, producing deeper remissions and better survival. This combination has made APL a curable disease for the large majority of patients.⁷

From Lethal to Curable

The trajectory of APL treatment over the past several decades is staggering. When the disease was first described in 1957, it was essentially a death sentence, with patients dying within weeks of diagnosis from hemorrhage.⁸ The introduction of chemotherapy with anthracyclines raised the complete remission rate to about 75 to 80 percent, but only about 35 to 45 percent of patients were ultimately cured. Adding ATRA to chemotherapy in the early 1990s pushed remission rates above 90 percent and five-year disease-free survival to around 74 percent. Then arsenic trioxide arrived, first for relapsed patients and eventually as front-line therapy, pushing outcomes higher still.⁹

A landmark trial (APL15) tested a chemotherapy-free strategy using ATRA plus ATO alone against ATRA plus ATO with added chemotherapy. Two-year disease-free survival was 98 percent in the chemotherapy-free arm and 97 percent in the chemotherapy arm, with no meaningful difference between them. Even among high-risk patients, defined by a white blood cell count above 10 × 10⁹/L, the chemotherapy-free approach achieved a two-year disease-free survival of 94 percent.¹⁰ For a cancer that once killed within weeks, the idea that most patients can now be cured without any conventional chemotherapy is a genuinely extraordinary development.

Risk Stratification and Who Needs Chemotherapy

Not all APL patients face the same risk of relapse. A widely used scoring system, known as the Sanz score, divides patients into risk categories based on their white blood cell and platelet counts at diagnosis. Standard-risk patients have a white cell count below 10 × 10⁹/L. High-risk patients, those with counts above that threshold, historically have higher relapse rates and were the group for whom adding cytarabine to anthracycline-based regimens showed the clearest benefit.¹¹

With the shift toward ATRA-plus-ATO regimens, even high-risk patients are doing well without traditional chemotherapy, as the APL15 trial demonstrated. Some centers still add a limited course of an anthracycline like idarubicin for high-risk patients receiving ATRA plus ATO, or use gemtuzumab ozogamicin (an antibody-drug conjugate) to blunt the initial white cell surge. But the direction of the field is clearly toward minimizing or eliminating conventional cytotoxic chemotherapy whenever possible.

Differentiation Syndrome

The same mechanism that makes ATRA and ATO so effective, forcing immature leukemia cells to mature, also creates a unique complication. As the malignant promyelocytes differentiate, they can provoke an intense inflammatory response. The resulting condition, called differentiation syndrome, is marked by unexplained fever, weight gain, respiratory distress, fluid accumulation around the lungs or heart, low blood pressure, and sometimes kidney failure.¹²

At the tissue level, maturing myeloid cells infiltrate the lungs, damage the endothelium, and cause edema and hemorrhage. The underlying mechanism is not fully worked out, but an exaggerated production of inflammatory signaling molecules and increased expression of adhesion molecules on the maturing APL cells seem to drive it.¹³ Differentiation syndrome can be fatal if missed, but it responds well to high-dose dexamethasone when caught early. Close monitoring during induction therapy, particularly watching for unexplained weight gain, dyspnea, or fever in the first couple of weeks, is critical.

Getting the Diagnosis Right

Because APL treatment must start immediately and differs fundamentally from the treatment of other acute leukemias, fast and accurate diagnosis is crucial. Under the microscope, APL cells typically look distinctive: heavily granulated promyelocytes, often with bundles of needle-like Auer rods. But the disease has a hypogranular variant that can fool an inexperienced eye, and relying on morphology alone is risky.

Genetic confirmation of the PML-RARα fusion is the gold standard. Fluorescence in situ hybridization (FISH) and conventional chromosome analysis (karyotyping) can detect the t(15;17) translocation, but rare cases exist where these methods miss it. In one reported case, a patient with all the classic features of APL showed trisomy 8 as the only visible chromosomal abnormality, with no t(15;17) on either karyotype or FISH. Only molecular testing (RT-PCR) and sequencing revealed the PML-RARα transcript.¹⁴ The practical takeaway: when the clinical picture strongly suggests APL, a negative FISH should not end the workup. Molecular testing should follow.

Tracking the Disease After Treatment

One of APL’s advantages, from a monitoring standpoint, is that the PML-RARα transcript provides a sensitive molecular marker for residual disease. Quantitative PCR can detect one leukemia cell among tens of thousands of normal cells, which means doctors can identify a relapse at the molecular level months before it would show up in a blood count or bone marrow biopsy.

Studies using this approach have found that patients whose PML-RARα transcript copies rise above a certain threshold, or who test positive on two consecutive samples during or after maintenance therapy, almost invariably relapse.¹⁵ This molecular surveillance has reshaped how clinicians manage the post-treatment period, enabling pre-emptive therapy before a full-blown relapse develops.

That said, the value of ongoing molecular monitoring depends on the timeframe. In the era of ATRA-plus-ATO front-line therapy, monitoring within the first year after finishing treatment is useful for catching the small number of high-risk patients who relapse. Beyond one year, late molecular relapse is very rare, which means the cost and inconvenience of continued testing provides diminishing returns.¹⁶

Atypical Variants That Do Not Play by the Rules

About 0.4 percent of genetically confirmed APL cases involve variant fusion genes, most commonly PLZF-RARα or NPM1-RARα, where a different partner gene replaces PML. These variants matter clinically because they do not respond to ATRA and ATO the same way. In a registry of nearly 2,900 APL patients, 11 had variant rearrangements. Complete remission was achieved in about 73 percent of those patients, and survival was also around 73 percent, both substantially lower than typical APL. The relapse rate was 43 percent.¹⁷

The PLZF-RARα variant is especially notorious for ATRA resistance, a finding that makes mechanistic sense: ATO and ATRA work by targeting the PML-RARα protein, and a fundamentally different fusion protein simply is not susceptible to the same degradation pathways. Patients with variant APL generally require conventional chemotherapy-based approaches, sometimes with stem cell transplant, and their prognosis, while improved from historical levels, remains much less favorable than classical APL.

When APL Comes Back

Relapse in APL has become uncommon with modern front-line therapy, but it does happen, particularly in high-risk patients or those who did not receive ATO up front. The approach to relapsed disease has evolved considerably. ATO-based regimens are now the preferred salvage therapy for patients who relapse after initial chemotherapy-based treatment.¹⁸

After achieving a second remission, the question becomes whether further consolidation is enough or whether a stem cell transplant is warranted. Data suggest that autologous transplant, using the patient’s own stem cells, offers better long-term outcomes than ATO-based therapy alone in this setting. One analysis found five-year overall survival of 78 percent for patients who underwent autologous transplant in second remission versus 42 percent for those treated with ATO alone.¹⁹ Donor (allogeneic) transplant is generally reserved for patients who relapse very early or who fail to achieve a second molecular remission, given its higher treatment-related risks.

Central nervous system involvement at relapse is a recognized but uncommon event. Studies have found the incidence low enough that routine preventive treatment of the spinal fluid (intrathecal prophylaxis) is not recommended, even in high-risk patients, because the risks of the procedure, including hemorrhage during lumbar puncture in a patient with a clotting disorder, outweigh the potential benefit.²⁰

APL During Pregnancy

APL during pregnancy poses an unusually difficult clinical dilemma. The disease cannot wait; the bleeding risk threatens both mother and fetus. But arsenic trioxide, one of the two drugs central to modern APL therapy, is a known teratogen and is avoided during pregnancy. ATRA is the mainstay of induction in pregnant patients, often combined with chemotherapy. In a systematic review, the overall complete remission rate for pregnant APL patients was about 89 percent, which is somewhat lower than the general APL population but still encouraging given the constraints.²¹

The timing of diagnosis matters enormously for the pregnancy itself. Women diagnosed during the first trimester face a much higher rate of pregnancy loss, with spontaneous and induced abortions occurring in 88 percent of first-trimester cases compared to 30 percent in the second trimester.²² Pre-term delivery is also common regardless of trimester. Once the baby is delivered, arsenic can be introduced for consolidation therapy. A separate analysis reported similar findings: a complete remission rate of 93 percent for mothers, but with pre-term deliveries in about 46 percent and fetal complications in roughly a quarter of cases.²³

APL in Children

APL in children follows broadly the same biology as in adults, with PML-RARα as the driving abnormality and similar sensitivity to ATRA-based therapy. The hypogranular variant shows up in a minority of pediatric cases, around 12 percent in one cohort, and tends to have a somewhat different surface-marker profile. About three-quarters of children with APL present with hemorrhagic symptoms at diagnosis or during induction, including, in rare cases, intracranial bleeding.²⁴ ATRA-related side effects in children include a condition called pseudotumor cerebri (increased intracranial pressure causing headaches and visual disturbances), which is somewhat more common in younger patients than in adults.

Life After APL

Survivorship after APL brings its own set of challenges that do not always get the attention they deserve. In a study of 365 long-term APL survivors at a median of nearly 11 years from diagnosis, roughly a quarter reported financial toxicity, and this financial burden was associated with significantly worse quality of life across multiple domains. Survivors who reported financial strain were far more likely to have emotional functioning problems, cognitive difficulties, and physical symptoms like shortness of breath compared to those without financial strain.²⁵

This finding is striking because the study was conducted within a universal healthcare system, where direct medical costs are largely covered. The financial burden came from other sources: loss of income, reduced work capacity, and comorbidities accumulated over years. Having even one comorbidity more than doubled the odds of reporting financial toxicity. These data are a reminder that curing the leukemia, as remarkable an achievement as that is, does not necessarily restore a patient’s overall well-being or financial stability.

The Cost Question

From a health-system perspective, the shift toward ATRA-plus-ATO has interesting economic implications. A cost-effectiveness analysis comparing front-line treatment strategies in the United States found that ATRA plus ATO was highly cost-effective relative to older chemotherapy-based regimens, with an incremental cost of about $5,600 per quality-adjusted life-year gained compared to ATRA plus idarubicin.²⁶ By any standard threshold used in health economics, that is an excellent value. The results were sensitive to the pharmacy cost of ATO during consolidation, though, which is worth noting given the wide variation in arsenic trioxide pricing across countries and healthcare systems.

In resource-limited settings, availability of ATO can still be a barrier, and some regions continue to rely on ATRA-plus-chemotherapy protocols that, while effective, carry more toxicity and modestly lower cure rates. Generic formulations of arsenic trioxide have helped broaden access, but the infrastructure needed for safe administration, including cardiac monitoring and laboratory support, remains a challenge in some parts of the world.